Heart failure market to grow at 9.6 per cent CAGR in 7MM during 2022-32 GlobalData Jan 8, 2025 GlobalData’s report reveals that the US will contribute the most to the growth of the HF market due to the higher prevalence of HF…
FINEARTS-HF trial results in clinically meaningful reduction in the composite endpoint of CV death EP News Bureau Aug 6, 2024 The study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which…
Bayer introduces medication for Chronic Kidney Disease Press Trust of India Aug 26, 2022 The drug is a non-steroidal, selective mineralocorticoid receptor antagonist indicated for patients with chronic kidney disease…
Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes EP News Bureau Jul 10, 2021 It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…